Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Non-Viral Nucleic Acid Delivery Strategies to the Central Nervous System.

Tan JY, Sellers DL, Pham B, Pun SH, Horner PJ.

Front Mol Neurosci. 2016 Nov 1;9:108. Review.

2.

Targeted axonal import (TAxI) peptide delivers functional proteins into spinal cord motor neurons after peripheral administration.

Sellers DL, Bergen JM, Johnson RN, Back H, Ravits JM, Horner PJ, Pun SH.

Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):2514-9. doi: 10.1073/pnas.1515526113.

3.

Mechanisms of Muscle Denervation in Aging: Insights from a Mouse Model of Amyotrophic Lateral Sclerosis.

Park KH.

Aging Dis. 2015 Oct 1;6(5):380-9. doi: 10.14336/AD.2015.0506. Review.

4.

Pathogen-inspired drug delivery to the central nervous system.

McCall RL, Cacaccio J, Wrabel E, Schwartz ME, Coleman TP, Sirianni RW.

Tissue Barriers. 2014 Aug 8;2(4):e944449. doi: 10.4161/21688362.2014.944449.

5.

Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons.

Restani L, Giribaldi F, Manich M, Bercsenyi K, Menendez G, Rossetto O, Caleo M, Schiavo G.

PLoS Pathog. 2012 Dec;8(12):e1003087. doi: 10.1371/journal.ppat.1003087.

6.

Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application.

Benkler C, Offen D, Melamed E, Kupershmidt L, Amit T, Mandel S, Youdim MB, Weinreb O.

EPMA J. 2010 Jun;1(2):343-61. doi: 10.1007/s13167-010-0026-1.

7.

Design and screening of a glial cell-specific, cell penetrating peptide for therapeutic applications in multiple sclerosis.

Heffernan C, Sumer H, Guillemin GJ, Manuelpillai U, Verma PJ.

PLoS One. 2012;7(9):e45501. doi: 10.1371/journal.pone.0045501.

8.

Tetanus toxin C-fragment: the courier and the cure?

Toivonen JM, Oliván S, Osta R.

Toxins (Basel). 2010 Nov;2(11):2622-44. doi: 10.3390/toxins2112622. Review.

9.

Apelin deficiency accelerates the progression of amyotrophic lateral sclerosis.

Kasai A, Kinjo T, Ishihara R, Sakai I, Ishimaru Y, Yoshioka Y, Yamamuro A, Ishige K, Ito Y, Maeda S.

PLoS One. 2011;6(8):e23968. doi: 10.1371/journal.pone.0023968.

10.

Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule.

Calvo AC, Moreno-Igoa M, Mancuso R, Manzano R, Oliván S, Muñoz MJ, Penas C, Zaragoza P, Navarro X, Osta R.

Orphanet J Rare Dis. 2011 Mar 21;6:10. doi: 10.1186/1750-1172-6-10.

11.

AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice.

Dodge JC, Treleaven CM, Fidler JA, Hester M, Haidet A, Handy C, Rao M, Eagle A, Matthews JC, Taksir TV, Cheng SH, Shihabuddin LS, Kaspar BK.

Mol Ther. 2010 Dec;18(12):2075-84. doi: 10.1038/mt.2010.206.

Items per page

Supplemental Content

Support Center